Health Alliance™

Pharmacy Drug Policy & Procedure

Policy Name:	Lokelma (sodium zirconium cyclosilicate)	Policy #:	2797P

Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of Lokelma (sodium zirconium cyclosilicate).

Statement of the Policy

Health Alliance Medical Plans and Health Alliance Northwest will approve the use of Lokelma when the following criteria have been met.

Criteria

1. Coverage Criteria
1.1   Documented diagnosis of hyperkalemia (high potassium)
1.2   Age 18 years or older
1.3   Prescribed by a specialist
1.4   Documented failure, intolerance, or contraindication to diuretic therapy, such as hydrochlorothiazide

2. Exclusions
2.1   Lokelma will not be covered in combination with Veltassa

3. Managed Dose Limit
3.1   #90 packets per 30 days

4. Approval Period
4.1   Initial Approval: 12 months
4.2   Subsequent Approvals: 12 months with documentation of beneficial response

CPT Codes

HCPCS Codes

References

1. Lokelma (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2024.
2. Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. J Am Soc Nephrol 2019; 30:1723.
3. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with

Hyperkalemia: A 12-Month Phase 3 Study. Clin J Am Soc Nephrol 2019; 14:798.

4. Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96 (3):744-762.
5. Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61

Created Date: 10/21/20
Effective Date: 10/21/20
Posted to Website: 01/01/22
Revision Date: 06/05/24